An interventional study of "PanTrek" and Physical Trainings in Obesity and Cognitive Change, sponsored by Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology. Recruiting at 1 site in Russian Federation. Open to female participants aged 60 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-05-06.
Sponsored by Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Obesity with a site in Russian Federation — 3 open to participants now, 4 under way, none of them phase 3. Obesity · Russian Federation.
Among the 33 studies in Obesity with a site in Russian Federation, this one is the 14th largest by planned enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2022, is one of 9 with no phase, and was the 27th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →3 of the 33 studies in Obesity with a site in Russian Federation are open now. Recruiting first, the newest first:
Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology · Sites in Russian Federation
Ages 50–80
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russian Federation
Ages 18+ · Healthy volunteers
A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 60 Years to 75 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 220 across the 24 interventional studies, 2,000 across the 9 observational. Of the 27 that completed or were terminated, 10 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 33 have an industry lead sponsor. The 10 most frequent:
Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology has 3 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 33 studies in Obesity with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
According to studies, the risk of cerebrovascular disease and cognitive decline are associated with age-related changes. In addition, there is data suggesting a relationship between the progression of this pathology and the presence of obesity and associated metabolic disorders. According to to some research, weight loss associated with cognitive function decline. In this regard, the development of effective, applicable in real clinical practice methods of non-drug treatment and prevention of cerebrovascular disorders and age-related cognitive decline in people with obesity and metabolic disorders, who are at high risk, seems to be extremely relevant.
The main goal of the study is to compare the effectiveness of various weight loss approaches and to study their effects on the cognitive functions of elderly obesity women.
The high prevalence of comorbid pathology characterised the elderly and senile population. Particularly, comorbid condition is often based on obesity. Also, an important characteristic of the elderly and senile age is the development of age-related cognitive deficit and progressive decline in cognitive functions, that is detected in 60.8% of people over 65 years old in Russia according to the EVKALIPT study.
The prevalence of obesity in the Russian population reaches 40% among the elderly population. According to studies, the presence of obesity is "paradoxically" associated with less progression of cognitive function loss, and the risk reduction in some populations reaches 40%. However, the sarcopenic obesity is an independent predictor of cognitive impairment in the elderly. Consequently, the therapy of obesity in elderly and senile population faces two important aspects: the risk of muscle loss and the development of sarcopenia and progressive cognitive decline. The described features of this age group are consistent with the well-known "obesity paradox", in which overweight and obesity are associated with longer life expectancy.
The risk of muscle mass reduction and cognitive functions decrease determines the formation of a specialised approach to obesity management in older population. Thus, the setting of softer and longer-term goals with a gradual decrease in body weight is typical. Studies have considered the use of various interventions, so far the combination of diet with exercise has proven effectiveness in muscle mass protection. At the same time, regular exercises reliably protect from cognitive decline. Thereby, the combination of diet and physical activity is considered as a suitable approach to obesity management in the elderly.
Recently, there have also been a number of studies evaluating the effectiveness of the ketogenic diet. This diet pattern is reliably effective in body weight reduction, skeletal muscle mass maintenance, and adipose tissue metabolism improvement in the elderly . Also, the neuroprotective effects of the ketogenic diet have been confirmed by meta-analyses and have made it possible to include it in current guidelines for the prevention and treatment of cognitive impairment. However, the high frequency of negative effects and the associated low adherence limit the possibilities of using this diet, which led to the development of exogenous ketones that allow reaching the levels of blood ketone bodies associated with neuroprotective properties (0.2-0.5 mmol/l) with better portability.
The main goal of the study is to compare the effectiveness of various weight loss approaches and to study their effects on the cognitive functions of elderly obesity women.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Product group is prescribed with the investigated product - exogeneous ketone bodies.
Dietary Supplement: "PanTrek"
The Combined Intervention Group is prescribed with the investigated product -in combination with regular physical trainings.
Dietary Supplement: "PanTrek" · Behavioral: Physical Trainings
The Placebo Group is prescribed with the Placebo.
Other: Placebo
The Diet Group is prescribed with the Diet designed with 500 kcal reduction from daily energy expenditure.
Behavioral: Diet
The Control Group is prescribed with standard recommendations for weight loss.
The intervention is represented by the investigational product "PanTrek", shots with liquid, 25 ml each (TU 10.89.19-01-44850857-2020). The composition of the product "PanTrek" (per 1 dose): * Ginseng dry extract (Panax ginseng Meyer) all parts of the plant - 125 mg (the amount of ginsenosides in one vial is 9.0 mg ± 3.5 mg); * Melissa officinalis dry extract (Melissa officinalis L) all parts of the plant - 340 mg (the amount of hydroxycinnamic acids is 19.50 mg / vial ± 10% in one vial); * Apple juice concentrated 2.5% - 7,5 g; * Potassium beta-hydroxybutyrate - 4,5 g; * Magnesium beta-hydroxybutyrate - 500 mg; * E211 sodium benzoate - no more than 5 mg; * E202 Potassium sorbate - no more than 3,6 mg; * Water purified - up to 25 ml. The product has registered as diet supplement in the Unified Register of Certificates of State Registration N RU.77.99.11.003.R.001152.04.21 from 05.04.2021.
Also known as: Exogenous ketone bodies
Physical activity is represented by 2 workouts lasting 45 minutes per week on an antigravity treadmill Alter-G M320 (AlterG, USA) and 2 sessions of reoxygenation lasting 30 minutes on a normobaric hypoxic therapy device ReOxy (Bitmos GmbH, Germany).
Also known as: Exercises
The placebo is represented by concentrated apple juice 2.5% - 7.5 g, potassium chloride - 2.405 g, MgCl2 - 0.382 g, sodium benzoate (E211) - 5 mg and potassium sorbate (E202) - 3.6 mg, brought to 25 ml of distilled water.
The studied diet is a low-calorie diet with an average energy value of 1730.16 kcal / day and a certain chemical composition (proteins - 108.80 g / day, fats - 68.10 g / day, carbohydrates - 162.60 g / day), including the main groups products (meat and poultry dishes, fish dishes, dairy products, cereals, vegetables and fruits). On average, 0.96-1.05 g of protein accounted for 1 kg of body weight of the subjects.
Change from baseline body weight at 12 weeks
The dynamics of body weight
Time frame: Baseline (visit 1) and after 12 weeks (visit 2)
Change from baseline Montreal Cognitive Assessment (MoCa) test scores at 12 weeks
The changes in the cognitive testing results
Time frame: Baseline (visit 1) and after 12 weeks (visit 2)
Change from baseline Trail Making Test (TMT) a&b test scores at 12 weeks
The changes in the cognitive testing results (normal range - less than 78 and 273 seconds (=scores)).
Time frame: Baseline (visit 1) and after 12 weeks (visit 2)
Change from baseline Word recall test scores at 12 weeks
The changes in the cognitive testing results (normal range as 45 words (=scores) and more out of 5 repetitions). Minimal - 0 (worse result), maximal score - 50 (excellent result).
Time frame: Baseline (visit 1) and after 12 weeks (visit 2)
Change from baseline Mean response time in the test "Schulte tables" at 12 weeks
The changes in the cognitive testing results
Time frame: Baseline (visit 1) and after 12 weeks (visit 2)
Change from baseline The Stroop Color and Word Test results at 12 weeks
The changes in the cognitive testing results
Time frame: Baseline (visit 1) and after 12 weeks (visit 2)
Change from baseline Verbal fluency test results at 12 weeks
The changes in the cognitive testing results
Time frame: Baseline (visit 1) and after 12 weeks (visit 2)
Change from baseline fat mass at 12 weeks
The changes in the fat mass according to the bioimpedance analysis
Time frame: Baseline (visit 1) and after 12 weeks (visit 2)
Change from baseline skeletal muscle mass at 12 weeks
The changes in the skeletal muscle mass according to the bioimpedance analysis
Time frame: Baseline (visit 1) and after 12 weeks (visit 2)
Change from baseline visceral fat at 12 weeks
The changes in visceral fat according to the bioimpedance analysis
Time frame: Baseline (visit 1) and after 12 weeks (visit 2)
Change from baseline total cholesterol serum levels at 12 weeks
The changes of total cholesterol serum levels
Time frame: Baseline (visit 1) and after 12 weeks (visit 2)
Change from baseline LDL-cholesterol serum levels at 12 weeks
The changes of LDL-cholesterol serum levels
Time frame: Baseline (visit 1) and after 12 weeks (visit 2)
Change from baseline HOMA-IR (homeostasis model assessment - insulin resistance) index at 12 weeks
The changes of HOMA-IR index
Time frame: Baseline (visit 1) and after 12 weeks (visit 2)
Change from baseline C-reactive protein (CRP) serum levels at 12 weeks
The changes of CRP serum levels
Time frame: Baseline (visit 1) and after 12 weeks (visit 2)
Change from baseline Tumor Necrosis Factor Alpha (TNFa) serum levels at 12 weeks
The changes of TNFa serum levels
Time frame: Baseline (visit 1) and after 12 weeks (visit 2)
Change from baseline systolic blood pressure (SBP) at 12 weeks
The changes of SBP
Time frame: Baseline (visit 1) and after 12 weeks (visit 2)
Change from baseline diastolic blood pressure (DBP) at 12 weeks
The changes of DBP
Time frame: Baseline (visit 1) and after 12 weeks (visit 2)
Change from baseline grip strength at 12 weeks
The changes of grip strength measured by grip dynamometer on the leading hand
Time frame: Baseline (visit 1) and after 12 weeks (visit 2)
Change from baseline Six Minute Walk Test distance at 12 weeks
The changes of Six Minute Walk Test results
Time frame: Baseline (visit 1) and after 12 weeks (visit 2)
Change from baseline Hamilton Anxiety Rating Scale at 12 weeks
The changes of Hamilton Anxiety Rating Scale results (normal range - 6 scores and less).
Time frame: Baseline (visit 1) and after 12 weeks (visit 2)
Change from baseline Hamilton Depression Rating Scale at 12 weeks
The changes of Hamilton Depression Rating Scale results (normal range - 7 scores and less).
Time frame: Baseline (visit 1) and after 12 weeks (visit 2)
Plan to share: No
Started Jan 2022 (actual). Primary completion is estimated for Jun 2023, 17 months after the start.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 17 months is below that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology